FDA accepts Revolution Medicines' NDA for daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma
https://finviz.com/stock?t=RVMD&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.